December 2024
Clinically, Yucca Health follows the common telehealth model of providing prescriptions without extensive wraparound support
However, if youre taking other diabetes medications, particularly insulin or sulfonylureas, the risk increases
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
And no worries because there are no reported side effects and no need for a prescription
Researchers utilize this mechanism to explore downstream effects on SIRT1 activation, which is a critical regulator of mitochondrial biogenesis, fat oxidation, and glucose metabolism
